Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in Diastolic Heart Failure
NCT00757055Phase 2Withdrawn
- Sponsor
- St. Vincent's University Hospital
- Start
- Dec 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Ivabradine with Placebo (2 arms). Primary endpoint: Echocardiographic indices of diastolic dysfunction at 12 weeks. Planned start Dec 2012; status: withdrawn.
02
Drugs
ivabradine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00757055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757055.